Relief Cardiovascular to Advance FIH Study of Relief System With New Financing

January 8, 2025—Relief Cardiovascular, an inQB8 Medical Technologies portfolio company developing solutions for the management of heart failure, announced the closing of a $12 million Series A financing.

According to the company, the funding will support further product development as well as the initiation of the company’s first-in-human (FIH) feasibility study to evaluate the safety and efficacy of the Relief system. The device is a transcatheter “smart” implant designed to monitor and modulate renal vein pressures for fluid management in heart failure.

As explained in the press release, the Relief system reduces renal vein pressure using a “puller” mechanism that is paired with integrated sensors to autonomously capture renal vein pressures and multiparametric data. The system provides actionable data for optimizing fluid management and offers tailored therapeutic device-driven intervention, noted Relief Cardiovascular.

“The Relief system’s ability to integrate monitoring and therapeutic modulation of renal pressures represents a promising advance in volume management in heart failure,” commented William T. Abraham, MD, in the press release.

Alex Rothman, MD, added, “By enabling data-driven adjustments, the Relief system empowers more personalized and effective care for patients, particularly those with diuretic resistance.”

Dr. Abraham is Professor of Medicine at The Ohio State University Wexner Medical Center in Columbus, Ohio. Dr. Rothman is Professor of Cardiology at the University of Sheffield in Sheffield, United Kingdom.

Relief Cardiovascular advised that the funding round was led by Broadview Ventures and Advent Life Sciences, with participation from Pacific Health Investment, Heartwork Capital, and an undisclosed multinational strategic.

As part of the financing, Shahzad Malik, MD, general partner at Advent Life Sciences, and Maria Berkman, MD, head of medtech at Broadview Ventures, will join the company’s board of directors, noted Relief Cardiovascular.